Skip to main content
. 2013 Oct 1;6(5):562–572. doi: 10.1593/tlo.13409

Figure 5.

Figure 5

Increased avidity leads to superior efficacy. (A) In vivo xenograft study (i.p. dosing, 30 mg/kg once weekly) and (B) in vitro cell proliferation assay (12 nM compounds present in media for whole experiment). *P < .05, ***P < .001 by two-way ANOVA with Bonferroni post-test. Arrows indicate dosing. (C) Phospho-Erk levels measured in tumors harvested at the end of the efficacy study; *P < .05 versus PBS-dosed tumors by two-tailed Student's t test. Dual staining of blood vessels and human IgG of the tumors at the end of the efficacy study; (D) monomer peptide IgG dosed and (E) homodimer peptide IgG dosed.